CD112 Lactylation Drives Dual Immune Evasion From CD8+ T Cells and NK Cells
Zhuoshuo Xu, Xinyu Zhang, Fang Dong, Nenghao Shen, Jun Zhou, Zihan Xi, Zhenghao Wu · 2026
Read CD112 Lactylation Drives Dual Immune Evasion From CD8+ T Cells and NK Cells by Zhuoshuo Xu, Xinyu Zhang, Fang Dong, Nenghao Shen, Jun Zhou, Zihan Xi, Zhenghao Wu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13634482.txt.
Description
Zhuoshuo Xu and co-authors report that lactylation of CD112 drives tumors to evade both CD8 T cells and natural killer cells. Their 2026 paper deals with a membrane checkpoint ligand that, unlike PD-L1, serves as a shared inhibitory signal for both cell types.
Current cancer immunotherapy mainly targets CD8 T cells, leaving natural killer surveillance largely unaddressed. In response to tumor lactate buildup, an enzyme lactylates CD112 at a specific lysine. That blocks a ligase that would tag it for lysosomal degradation. CD112 is thus stabilized at the cell surface, and tumor cells evade both adaptive and innate killers. Disrupting the axis restored immune surveillance in their tests.
Catalog record
| CREATOR | Zhuoshuo Xu, Xinyu Zhang, Fang Dong, Nenghao Shen, Jun Zhou, Zihan Xi, Zhenghao Wu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 109 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |